Switch theme
Sign up to access all valuation multiples
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.
2014
26
LTM Revenue $2.1M
Last FY EBITDA -$15.6M
$5.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Longeveron has a last 12-month revenue (LTM) of $2.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Longeveron achieved revenue of $2.4M and an EBITDA of -$15.6M.
Longeveron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Longeveron valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1M | XXX | $2.4M | XXX | XXX | XXX |
| Gross Profit | $1.7M | XXX | $1.9M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$15.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -651% | XXX | XXX | XXX |
| EBIT | -$18.7M | XXX | -$16.5M | XXX | XXX | XXX |
| EBIT Margin | -877% | XXX | -691% | XXX | XXX | XXX |
| Net Profit | -$23.9M | XXX | -$16.0M | XXX | XXX | XXX |
| Net Margin | -1120% | XXX | -668% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Longeveron's stock price is $1.
Longeveron has current market cap of $18.6M, and EV of $5.6M.
See Longeveron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.6M | $18.6M | XXX | XXX | XXX | XXX | $-2.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Longeveron has market cap of $18.6M and EV of $5.6M.
Longeveron's trades at 2.3x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Longeveron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Longeveron has a P/E ratio of -0.8x.
See valuation multiples for Longeveron and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.6M | XXX | $18.6M | XXX | XXX | XXX |
| EV (current) | $5.6M | XXX | $5.6M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLongeveron's last 12 month revenue growth is -1%
Longeveron's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Longeveron's rule of 40 is -2833% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Longeveron's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Longeveron and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -651% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2833% | XXX | -651% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 340% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 769% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Longeveron acquired XXX companies to date.
Last acquisition by Longeveron was XXXXXXXX, XXXXX XXXXX XXXXXX . Longeveron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Longeveron founded? | Longeveron was founded in 2014. |
| Where is Longeveron headquartered? | Longeveron is headquartered in United States of America. |
| How many employees does Longeveron have? | As of today, Longeveron has 26 employees. |
| Who is the CEO of Longeveron? | Longeveron's CEO is Mr. Mohamed Wael Ahmed Hashad. |
| Is Longeveron publicy listed? | Yes, Longeveron is a public company listed on NAS. |
| What is the stock symbol of Longeveron? | Longeveron trades under LGVN ticker. |
| When did Longeveron go public? | Longeveron went public in 2021. |
| Who are competitors of Longeveron? | Similar companies to Longeveron include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Longeveron? | Longeveron's current market cap is $18.6M |
| What is the current revenue of Longeveron? | Longeveron's last 12 months revenue is $2.1M. |
| What is the current revenue growth of Longeveron? | Longeveron revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Longeveron? | Current revenue multiple of Longeveron is 2.6x. |
| Is Longeveron profitable? | Yes, Longeveron is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
